Product Description
Broncho-Vaxom is effective and safe for the treatment of acute episodes of respiratory tract infections and for preventing recurrences.
Mechanisms of Action: Immunostimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Brazil | Bulgaria | Chile | Czech | Egypt | Germany | Greece | Hungary | Indonesia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Switzerland | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: OM Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Germany, Hungary, Poland, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Dermatitis, Atopic|Other|Respiratory Sounds
Phase 1: Asthma, Allergic|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BV-2020/09 | P2 |
Unknown Status |
Other |
2026-02-28 |
|
BV-2020/09 | P2 |
Recruiting |
Respiratory Sounds |
2025-08-28 |
|
BV-2022/11 | P1 |
Recruiting |
Asthma, Allergic |
2025-02-28 |
|
2021-003179-33 | P2 |
Active, not recruiting |
Dermatitis, Atopic |
2024-03-29 |